Advanced Biomed (ADVB) vs Sera Prognostics (SERA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Sera Prognostics (SERA) has outperformed Advanced Biomed (ADVB) over the past year, losing 44.0% versus a loss of 77.8%. Sera Prognostics is the larger company by market cap ($72.0 million vs $2.7 million), about 26.4 times the size. Advanced Biomed converts more of its revenue into profit, with a net margin of 5231.3% versus -39417.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADVB | SERA |
|---|---|---|
| Share price | $1.65 | $1.81 |
| Market cap | $2.73M | $71.98M |
| 1-day change | -5.71% | -4.23% |
| YTD return | -71.75% | -38.64% |
| 1-year return | -77.76% | -43.96% |
| 5-year return | — | -83.55% |
| EPS (TTM) | $-5.03 | $-0.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $127.64K | $81.00K |
| Revenue growth (YoY) | — | +5.19% |
| Net income (latest FY) | $6.68M | $-31.93M |
| Gross margin | — | -102.47% |
| Operating margin | -4883.80% | -45066.67% |
| Net margin | 5231.30% | -39417.28% |
| 52-week high | $24.23 | $3.85 |
| 52-week low | $1.58 | $1.56 |
| Distance from 52-week high | -93.19% | -52.99% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +203.87% |
| Average volume | 88.38K | 27.84K |
| Shares outstanding | 1.65M | 38.80M |
| Employees | 31 | 71 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Sera Prognostics is about 26.4 times larger than Advanced Biomed by market value ($71.98M vs $2.73M).
- SERA has outperformed ADVB by 33.8 percentage points over the past year.
- Advanced Biomed is more profitable, keeping 5231.3 cents of every revenue dollar as net income versus -39417.3 cents for Sera Prognostics.
About Advanced Biomed
ADVB stock →Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, an automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cell (CTC) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product.
Health Care · Medical Specialities · 31 employees
About Sera Prognostics
SERA stock →Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation.
Health Care · Medical Specialities · 71 employees
ADVB vs SERA FAQ
Which is bigger, Advanced Biomed or Sera Prognostics?
Sera Prognostics (SERA) is larger, with a market capitalization of $71.98M compared with $2.73M for Advanced Biomed (ADVB).
Which stock has performed better over the past year, ADVB or SERA?
SERA returned -43.96% over the past 12 months, compared with -77.76% for ADVB (price return, excluding dividends). Past performance does not predict future results.
Are Advanced Biomed and Sera Prognostics in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.